个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共9条记录   How Does NICE Value Innovation? [作者：Garner, S,期刊：Drug Development Research, 页码：449-456 , 文章类型： Article，,卷期：2010年71-8] No country can afford all the health care interventions that might benefit patients. Demand will always outstrip available resources, so priorities have to be agreed upon. Such decisions are controversial, making it vita... The Increasing Role of Health Economic Evaluations in Drug Development [作者：Annemans, L; Cleemput, I; Simoens, S; Arickx, F; Hulstaert, F; Bogaert, M,期刊：Drug Development Research, 页码：457-462 , 文章类型： Article，,卷期：2010年71-8] The goal of health care policies is to maximize the health of the population within the limits of the available budget and taking into account equity considerations. For innovative drugs, this means that an increasing nu... Meeting the Information Needs of a National Drug Payer: Aspirations of the Guidelines from Australia [作者：Mitchell, AS; Viney, R,期刊：Drug Development Research, 页码：463-469 , 文章类型： Article，,卷期：2010年71-8] The information needs of drug payers at the provincial or national level are reasonably similar across the world. Until recently, the evidence generated to meet these needs has been largely intended to meet the informati... Using an Iterative Approach to Economic Evaluation in the Drug Development Process [作者：Boyd, KA; Fenwick, E; Briggs, A,期刊：Drug Development Research, 页码：470-477 , 文章类型： Article，,卷期：2010年71-8] The pharmaceutical industry has a well-known and formally recognized process for drug development, consisting of four distinct phases of clinical assessment. Similar to this drug development process, there is a five-stag... Pharmaceutical Market Access and the Challenges of Health Technology Assessment in the United Kingdom [作者：Tolley, K,期刊：Drug Development Research, 页码：478-484 , 文章类型： Article，,卷期：2010年71-8] Health Technology Assessment (HTA) has been formally used in the United Kingdom for more than 10 years to help determine evidence-based decisions on the access to new drugs, based on evidence of clinical and cost-effecti... Impact of DNA Patents on Pharmacogenomics Research and Development: Economic and Policy Issues [作者：Paci, D; Hopkins, MM; Zika, E; Ibarreta, D,期刊：Drug Development Research, 页码：485-491 , 文章类型： Article，,卷期：2010年71-8] The science of pharmacogenetics and pharmacogenomics (or collectively PGx) has advanced rapidly in recent years, and some technologies based on these developments have entered into use. It is notable that these advances ... Economic Evaluations of Pharmacogenetic and Genomic Screening Programs: Update of the Literature [作者：Vegter, S; Jansen, E; Postma, MJ; Boersma, C,期刊：Drug Development Research, 页码：492-501 , 文章类型： Article，,卷期：2010年71-8] Pharmacogenetics and pharmacogenomics show great potential for developing individual treatment modalities to achieve optimal therapy effectiveness. Economic analyses are performed to determine whether pharmacogenetic scr... Implementation of Innovative Pharmacogenetic Tests into Practice in Taiwan: An Institutional Perspective [作者：Chen, HY; Chen, LC,期刊：Drug Development Research, 页码：502-506 , 文章类型： Article，,卷期：2010年71-8] Pharmacogenetic tests are proposed as a means of targeting therapy to patients such that ineffective medicine prescription and adverse events are reduced and overall benefit in terms of improved health outcomes is maximi... Informing Resource Allocation Decision Making: Economic Evaluations of Pharmacogenetic Tests [作者：Payne, K; Gurwitz, D,期刊：Drug Development Research, 页码：445-448 , 文章类型： Editorial Material，,卷期：2010年71-8] In some countries, economic evaluations now have a prominent role and provide information to use in resource allocation decisions for health care technologies and interventions. This editorial describes the importance of...